Home » Topics » BioWorld Science

BioWorld Science
RSS

Storm Therapeutics identifies new METTL3 inhibitors

May 3, 2022

New EGFR inhibitors discovered at the Dana-Farber Cancer Institute

May 3, 2022

OQL-051 shows prophylactic efficacy in models of chemotherapy-induced diarrhea

May 3, 2022

Bridge Biotherapeutics and Cyrus Therapeutics generate next-generation EGFR degraders

May 2, 2022

BioNova Pharmaceuticals menin inhibitor BNM-1192 shows promise for MLL rearranged leukemias

May 2, 2022

CF-370 shows synergy with amikacin in drug-resistant P. aeruginosa acute pneumonia model

May 2, 2022

Innate immune memory underlies inflammatory comorbidities: study

May 2, 2022

New mucolipin-1 activators identified at Lysoway Therapeutics

May 2, 2022

Curome Biosciences presents new quinone derivatives

May 2, 2022

Vertex Pharmaceuticals discovers CFTR modulators

May 2, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...